New hope for tough leukemia: Three-Drug combo trial launches

NCT ID NCT06621212

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of three drugs—mitoxantrone liposome, cytarabine, and venetoclax—in 72 adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if this combo can help more patients achieve complete remission. Participants will receive the drugs in cycles and be monitored for response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mitoxantrone hydrochloride liposome, cytarabine, and venetoclax
What this could lead to: If successful, this combination could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia that has returned or not responded to prior therapy.
What could go wrong: This is an early phase 2 study with only 72 participants, so results may not apply to all patients. The drug combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOID MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOID MALIGNANCY RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA

Contacts and locations

Locations

The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.